CATALOGO DEI PRODOTTI DELLA RICERCA

TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.525
EU - Europa 10.259
AS - Asia 3.989
OC - Oceania 35
SA - Sud America 35
Continente sconosciuto - Info sul continente non disponibili 30
AF - Africa 8
Totale 24.881
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.492
GB - Regno Unito 4.414
CN - Cina 3.120
IE - Irlanda 961
SE - Svezia 925
FR - Francia 901
IT - Italia 782
DE - Germania 709
RU - Federazione Russa 641
FI - Finlandia 587
SG - Singapore 495
UA - Ucraina 151
VN - Vietnam 141
BE - Belgio 53
KR - Corea 53
NL - Olanda 39
JP - Giappone 37
TR - Turchia 31
AU - Australia 29
EU - Europa 27
CA - Canada 25
IN - India 22
IR - Iran 21
CL - Cile 15
AT - Austria 13
CH - Svizzera 13
PL - Polonia 10
PE - Perù 9
HK - Hong Kong 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
BR - Brasile 7
CZ - Repubblica Ceca 7
BG - Bulgaria 6
LK - Sri Lanka 6
NZ - Nuova Zelanda 6
RO - Romania 6
LV - Lettonia 5
MY - Malesia 5
BD - Bangladesh 4
EE - Estonia 4
GR - Grecia 4
HU - Ungheria 4
IL - Israele 4
MK - Macedonia 4
MX - Messico 4
PH - Filippine 4
UZ - Uzbekistan 4
ES - Italia 3
ID - Indonesia 3
MA - Marocco 3
NO - Norvegia 3
PT - Portogallo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
EC - Ecuador 2
KZ - Kazakistan 2
LU - Lussemburgo 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A1 - Anonimo 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
EG - Egitto 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
PA - Panama 1
PK - Pakistan 1
TM - Turkmenistan 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 24.881
Salva come PNG Salva come JPEG
Città #
Southend 4.196
Chandler 1.857
Jacksonville 1.438
Woodbridge 1.417
Ann Arbor 1.008
Dublin 960
Houston 593
Beijing 574
Ashburn 524
Lawrence 397
Princeton 397
Wilmington 377
Jinan 318
Singapore 318
Nanjing 276
Shenyang 262
Verona 208
Hebei 169
New York 156
Tianjin 155
Changsha 123
Nanchang 101
Haikou 93
Zhengzhou 93
Ningbo 87
Sindelfingen 83
Hangzhou 79
Dong Ket 78
Helsinki 77
Jiaxing 74
Milan 71
Guangzhou 61
Taizhou 59
Redwood City 58
Norwalk 54
Taiyuan 54
Brussels 53
Boardman 47
Seoul 45
Lanzhou 43
Seattle 39
Lancaster 38
Bologna 36
Fuzhou 36
Los Angeles 36
Falls Church 34
Dearborn 32
San Francisco 30
Redmond 29
Kent 28
Tokyo 28
Chicago 27
Dongguan 26
Dallas 23
Washington 22
Düsseldorf 19
Fairfield 18
Augusta 17
Clearwater 17
Toronto 14
Rome 13
San Mateo 12
Sydney 11
Melbourne 10
Detroit 9
Groningen 9
San Diego 9
Amsterdam 8
Auburn Hills 8
Nürnberg 8
Vienna 8
Ardabil 7
Baku 7
Canberra 7
Renton 7
Riva 7
Colombo 6
Kochi 6
Lima 6
London 6
Padova 6
Prague 6
Fremont 5
Leawood 5
Markgröningen 5
Moscow 5
Paris 5
Qingdao 5
Sofia 5
Stockholm 5
Tappahannock 5
Yicheng 5
Zanjan 5
Bari 4
Brugnera 4
Catanzaro 4
Dhaka 4
Duncan 4
Florence 4
Frankfurt am Main 4
Totale 17.841
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 203
Whole-genome landscape of pancreatic neuroendocrine tumours 161
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 148
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 143
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 137
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 134
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 133
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 130
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 127
Genomic analyses identify molecular subtypes of pancreatic cancer 127
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 122
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 122
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 121
Reporting tumor molecular heterogeneity in histopathological diagnosis 120
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 119
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 115
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 114
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay 110
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 108
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 108
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 106
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 106
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 106
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 106
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 105
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 105
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 104
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 103
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 103
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 102
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 102
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 102
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 101
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 101
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 100
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 99
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 99
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 99
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 99
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 99
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 98
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 98
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms 98
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 98
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 97
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 97
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 97
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 97
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 96
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 96
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 96
Adenocarcinoma of the paraurethral glands: a case report 95
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 95
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 95
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 94
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 94
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 94
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 94
Profiling mTOR pathway in neuroendocrine tumors. 93
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 93
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 92
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 91
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 91
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 91
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 91
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 90
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 90
ESGAR 2016 Book of Abstracts 90
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 88
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 88
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 87
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 87
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 87
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 87
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 87
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 86
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 85
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 85
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 85
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 84
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 83
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 83
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 82
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 82
Angiogenesis: A target for cancer therapy. 81
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 81
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 81
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 80
The route to personalized medicine in bladder cancer: where do we stand? 80
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 79
ZD1839 (Iressa): preclinical studies and pharmacology. 79
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 79
Clinical meta-analyses of targeted therapies in adenocarcinoma. 79
Hypermutation In Pancreatic Cancer 79
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 79
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 78
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 78
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 78
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. 78
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 77
Totale 9.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.022
article - articoli 81.529
book - libri 210
conference - conferenze 6.259
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.024
Totale 180.044
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.282 0 0 27 229 308 261 337 189 155 298 217 261
2020/20213.001 292 599 130 371 474 236 33 152 143 76 307 188
2021/20222.735 204 783 17 211 94 46 41 175 109 61 199 795
2022/20235.509 474 505 555 863 538 1.411 55 324 586 36 118 44
2023/20242.411 104 203 180 202 382 381 51 232 45 125 353 153
2024/2025975 401 446 128 0 0 0 0 0 0 0 0 0
Totale 25.278